Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
|Articles|September 3, 2007
New HIV drug first to target CCR5 receptor
A drug with a new mechanism of action is always a welcome addition in the fight against HIV. Maraviroc was recently approved by the FDA and is the first of the chemokine receptor 5 antagonists to enter the market.
Advertisement
Advertisement
Related to this article
The once daily tablet is expected to reach US patients in October 2026.
The label expansion adds patients 12 years of age and older to the once daily alopecia areata indication.
Pharmacist and public health expert Jennifer Hammons, PharmD, DrPH, discusses pharmacy as essential infrastructure amid rural pharmacies persistently being overlooked.
An American Heart Association scientific statement shows earlier risk factors and social barriers driving cardiovascular disparities in Hispanic adults.
In an exploration of 2 distinct timeframes in the 21st century, researchers examine the use and concurrent use of medication types among elderly US adults.
The investigational anti–IL-33 antibody lowered exacerbation rates across all blood eosinophil levels, a benefit current COPD biologics do not offer.
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
Advertisement
Advertisement
Trending on Drug Topics
1
Muscle Preservation Is Key in GLP-1 Therapy for Postmenopausal Women
2
Tozorakimab Reduces COPD Exacerbations in Phase 3 Trials
3
Early CGMs Results in Better 5-Year Glucose Control in Type 1 Diabetes
4
Polypharmacy, Drug Interactions Threaten Older Adults’ Medication Safety
5